Peptide comparison
They belong to the same class: dual agonists that activate the GLP-1 and glucagon receptors at the same time. That combination aims to add increased energy expenditure and effects on liver fat to the effect on appetite. What sets them apart is the design of each molecule and its clinical path.
Compare mechanism, class, receptors and evidence. All compounds are offered with ≥99% purity verified by HPLC and a batch COA.
| Mazdutide | Survodutide | |
|---|---|---|
| Class | Dual GLP-1 / glucagon agonist | Dual GLP-1 / glucagon agonist |
| Development codes | LY3305677 / IBI362 | BI 456906 |
| Long-acting strategy | Lipidation (weekly action) | Lipidation (weekly action) |
| Research focus | Weight and glycaemic control | Weight control and metabolic liver disease (MASH) |
| Clinical development | Phase 3 programme centred on China | International phase 3 programme |
| Key difference | Its own balance between the two receptors | Its own balance between the two receptors |
Both molecules start from the same idea: a “hybrid” peptide with features of GLP-1 and oxyntomodulin/glucagon that activates both receptors. The GLP-1 component provides the effect on satiety and glucose; the glucagon component, higher energy expenditure and mobilisation of liver fat. How much activity each molecule has at each receptor (its balance) is what defines its profile, and it differs between them.
Mazdutide has been developed mainly in China, with phase 3 trials in weight control and type 2 diabetes. Survodutide has an international phase 3 programme that includes, besides weight control, metabolic dysfunction-associated steatohepatitis (MASH), an area where the glucagon component is especially relevant. Compared with retatrutide, both lack the GIP receptor.
💡 Want the complete scientific foundations? See the Peptide guide or the Certification in Peptide Science.
Yes. Both are dual agonists of the GLP-1 and glucagon receptors. They differ in molecular design, receptor balance and clinical programme.
Tirzepatide combines GLP-1 with GIP, not with glucagon. The glucagon component is associated with higher energy expenditure and effects on liver fat.
Retatrutide is a triple agonist: besides GLP-1 and glucagon, it activates the GIP receptor.
Purity ≥99% verificada por HPLC and batch COA.
View full catalog →